Biodesix, Inc.

NASDAQ:BDSX

Medical - Diagnostics & Research

Healthcare
$8.40 +13.40%

+$2.04 today

Market cap
$68.38M
Beta
0.59
P/E (TTM)
-5.2
EPS (TTM)
-$3.31
52W Low $5.00High $20.21

Volume 0.17M

Average 0.06M

BDSX Total Non-current Assets

All assets not expected to be converted to cash within one year.

Biodesix, Inc.NASDAQ: BDSX

Total Non-current Assets · Q1 FY2026 · quarter ended Mar 2026

Total non-current assets falls 5.1% from a year ago

Total non-current assets stood at $53.73M at the end of Q1 FY2026, down 5.1% from a year earlier and down 2.2% from the prior quarter. Over 3 fiscal years it compounded at +11.6% a year.

Context

  • Total non-current assets amounted to 56.8% of total assets at the end of Q1 FY2026, down 8.9 pp from a year earlier.
  • Total non-current assets increased in 1 of the last 3 fiscal years.

What to watch

Whether total non-current assets keeps falling in the next quarterly balance sheet after a -5.1% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$53.73M-2.2% QoQ
Last fiscal yearDec 2025
$54.96M-4.9% YoY
Year agoMar 2025
$56.62M-5.1% since
Total Non-current Assets past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-5.1%——
1 year-4.9%——
3-year CAGR+11.6%——
5-year CAGR——
10-year CAGR——

Total Non-current Assets history

USD · from the balance sheet

Latest · FY2025
54.96M USD
Year-over-year change
-4.9%
4-year CAGR
+14.0%

Total Non-current Assets vs competitors

How BDSX compares with its peers on the latest reported figures

  • BDSX's Mar 2026 total non-current assets of $53.73M is the highest of the 5 companies compared; the peer median is $2.39M.
  • Its year-over-year change of -5.1% is the highest of 5, against a peer median of -45.1%.
  • Total non-current assets amounts to 56.8% of total assets for BDSX, versus a peer median of 6.4%.
BDSX Competitors Peer median
Total Non-current Assets for BDSX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
BDSXBiodesix, Inc.Mar 2026$53.73M -5.1%+11.6%56.8%
XLOXilio Therapeutics, Inc.Mar 2026$9.28M -11.8%-13.0%5.7%
INMBINmune Bio, Inc.Mar 2026$3M -82.2%-47.6%11.6%
PDSBPDS Biotechnology CorporationMar 2026$1.78M -61.0%+61.9%7.2%
OKUROnKure Therapeutics, Inc.Mar 2026$1.21M -29.1%-18.7%0.6%
Peer median (excluding BDSX) $2.39M-45.1%-15.8%6.4%

Competitors are the stored peer set for BDSX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents32.71M43.09M26.28M26.25M18.99M
Short-term Investments00000
Net Receivables3.66M5.07M7.68M8.6M9.04M
Inventory2.9M1.4M1.4M00
Other Current Assets7.25M5.18M4.32M4.64M4.5M
Total Current Assets43.61M53.33M39.68M39.48M32.52M
Property, Plant & Equipment (Net)4.18M8.82M29.61M29.6M27.81M
Goodwill15.03M15.03M15.03M15.03M15.03M
Intangible Assets11.62M9.8M7.91M5.87M3.88M
Long-term Investments00000
Tax Assets00000
Other Non-current Assets1.66M5.92M6.86M7.26M8.23M
Total Non-current Assets32.48M39.57M59.41M57.76M54.96M
Total Assets76.1M92.91M99.1M97.24M87.48M
Account Payables1.66M1.69M2.93M2.19M3.08M
Short-term Debt19K49K51K21K6K
Tax Payables00000
Deferred Revenue1.85M962K324K678K961K
Other Current Liabilities21.4M15.05M26.01M792K8.83M
Total Current Liabilities28.96M22.84M33.42M14.32M17.44M
Long-term Debt9.99M25M35.23M36.41M47.45M
Deferred Tax Liabilities0(400K)000
Deferred Revenue (Non-current)0400K000
Other Non-current Liabilities17.42M19.2M712K815K1.02M
Total Non-current Liabilities27.41M49.46M61.1M62.05M72.51M
Total Liabilities56.37M72.3M94.52M76.37M89.94M
Common Stock31K78K96K145K8K
Retained Earnings(301.97M)(367.42M)(419.57M)(462.5M)(497.76M)
Accumulated OCI00000
Other Stockholders Equity00000
Minority Interest00000
Total Equity19.73M20.61M4.58M20.88M(2.47M)
Total Debt10.01M31.85M60.69M61.98M72.85M
Net Debt(22.7M)(11.24M)34.41M35.73M53.87M

Biodesix, Inc.

NASDAQ:BDSX

Intrinsic Alpha fair value

Locked

Current Price

$8.40

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.